Hiv replication inhibiting purine derivatives
CA 2535313 C · Owner: Vandenput, Dirk Alfons Leo · Inventors: Koymans, Lucien Maria Henricus; Vandenput, Dirk Alfons Leo; De Jonge, Marc Rene
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of HIV infection , wherein the compound of formula (I) is a compound of formula (see formula I), a N-oxide, a pharmaceutically acceptable addition salt a quaternary amine or , a , stereochemically isomeric form thereof wherein A and B each represents a , radical of formula, (see formula a) or (see formula b) and wherein -C-Drepresents a bivalent radical of formula -N=CH-NR17- (c-1); or , -NR17-CH=N- (c-2); provided that when A represents a radical of formula (a) then B represents a radical of , formula (b) and when A represents a radical of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 21, 2004 and granted July 17, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 21, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 21, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.